Long R3 IGF-1 · 83 amino acid IGF-1 analogue · Extended half-life
A synthetic 83-amino acid analogue of insulin-like growth factor 1 (IGF-1), engineered with two structural modifications: an arginine substitution at position 3 and a 13-amino acid N-terminal extension. These changes extend half-life from minutes to 20–30 hours and dramatically reduce binding to IGF binding proteins, increasing bioavailability. The most potent anabolic peptide commonly available — and the one with the most significant risk profile.
01 — Research Summary
The evidence base for IGF-1 LR3 draws primarily from native IGF-1 research and from the FDA-approved IGF-1 analogue mecasermin (Increlex), which was approved for severe IGF-1 deficiency in children. IGF-1 LR3 itself has no approved drug indication. The bodybuilding and performance community uses it based on extrapolation from this mechanistic and clinical literature, combined with an extensive real-world use dataset.
FDA-approved IGF-1 replacement therapy establishes mechanism credibility. Mecasermin (native recombinant IGF-1) is FDA-approved for severe primary IGF-1 deficiency — confirming that direct IGF-1 receptor activation produces the predicted anabolic effects in humans. LR3 acts through the same receptor with extended duration.
Consistent lean mass increases and fat reduction in animal models. Animal studies confirm IGF-1 LR3 produces lean mass gains, improved nitrogen retention, and fat oxidation via PI3K/Akt/mTOR pathway activation. The extended half-life produces substantially greater systemic exposure than native IGF-1.
IGF-1 receptor signalling is a well-established growth pathway for multiple cancers. Epidemiological data links chronically elevated IGF-1 to increased risk of colorectal, prostate, and breast cancer. IGF-1 LR3's 20–30 hour half-life produces substantially more sustained IGF-1R stimulation than either endogenous IGF-1 or GH secretagogue-driven IGF-1. The cancer risk is theoretical for short cycles in healthy individuals — but it is not hypothetical at the pathway level. Anyone with personal or family history of hormone-sensitive cancers should not use this compound.
02 — Mechanism of Action
IGF-1 LR3 binds directly to IGF-1 receptors on muscle, bone, adipose, and other tissues — bypassing the GH/liver/IGF-1 axis and delivering IGF-1 receptor activation with sustained 20–30 hour exposure.
IGF-1 LR3 binds IGF-1 receptors (IGF-1R) on target tissues with high affinity, activating receptor tyrosine kinase signalling. The key difference from GH secretagogues: this bypasses the pituitary-liver axis and delivers the anabolic signal directly to peripheral tissues.
IGF-1R activation triggers the PI3K/Akt pathway, which activates mTOR — the master regulator of protein synthesis. This drives both increased muscle protein synthesis (hypertrophy) and potentially new muscle cell formation (hyperplasia) — the mechanism most relevant to its bodybuilding use.
The LR3 modification reduces binding affinity to IGF binding proteins (IGFBPs), which normally sequester circulating IGF-1 and limit its bioavailability. This means a greater proportion of administered LR3 is free to bind IGF-1 receptors — amplifying the effective dose compared to native IGF-1.
IGF-1R shares structural similarity with the insulin receptor. At higher doses, IGF-1 LR3 produces insulin-like metabolic effects including enhanced glucose uptake in muscle — but also the risk of hypoglycaemia that makes this the most practically dangerous compound in this class.
03 — Dosing Context
The most important practical consideration for IGF-1 LR3 is hypoglycaemia risk. The compound should never be used without food available and blood glucose monitoring, particularly at higher doses.
| Experience level | Dose | Frequency | Cycle length | Key note |
|---|---|---|---|---|
| Conservative | 20–40 mcg | Daily | 4 weeks on / 4+ weeks off | Assess hypoglycaemia response |
| Standard community | 40–60 mcg | Daily | 10 days on / 4 weeks off | 10-day cycle most referenced |
| Upper range | 80–100 mcg | Daily | 10 days maximum | Significant hypoglycaemia risk |
The 10-day-on / 4-week-off cycling structure is the most commonly referenced community protocol — designed to prevent IGF-1R downregulation from continuous stimulation and to limit cumulative IGF-1R exposure. Unlike most peptides, administering IGF-1 LR3 fasted is specifically not recommended due to hypoglycaemia risk. Post-workout or post-meal administration is standard.
Stacking IGF-1 LR3 with exogenous insulin dramatically increases hypoglycaemia risk. Both lower blood glucose through different mechanisms. Severe hypoglycaemia from IGF-1 therapy caused serious adverse events in the Increlex clinical program. This is a real, documented risk — not theoretical. Have fast-acting carbohydrates available whenever dosing.
04 — Community
IGF-1 LR3 is discussed almost exclusively in the bodybuilding and performance community rather than the longevity or general wellness communities. The compound's potency and risk profile create a more serious, technically-oriented discussion than most peptides. Users with experience tend to be meticulous about cycle structure, dose precision, and blood glucose monitoring. Beginners who underestimate the hypoglycaemia risk are the source of most negative experiences reported.
The most consistently reported positive effects are accelerated lean mass gains and dramatically improved recovery during the active cycle period. Most experienced users treat it as an advanced tool rather than a starting point, typically having used GH secretagogue stacks first.